Since 2014, the Swiss Smarter medicine - choosing wisely campaign has established lists of recommendations, with an emphasis on futile treatments and tests where risks may outweigh benefits. Ultimately this initiative aims to develop, disseminate and implement educational programs to improve quality of care. Literature shows a positive impact of this initiative on clinical practice. Hence, we developed several guidelines based on this initiative in our internal medicine department. This article describes the multimodal and interprofessional strategy aiming to reduce neuroleptic prescriptions in acute delirium. After the implementation of this recommendation in our clinical practice, we noted positive effects, both qualitative and quantitative, confirming the potential benefit of such changes.

Download full-text PDF

Source

Publication Analysis

Top Keywords

neuroleptic prescriptions
8
prescriptions acute
8
clinical practice
8
[how fight
4
fight overtreatment
4
overtreatment example
4
example neuroleptic
4
acute delirium]
4
delirium] 2014
4
2014 swiss
4

Similar Publications

Antipsychotic off-label use in the 21st century: An enduring public health concern.

Dialogues Clin Neurosci

December 2025

University Bordeaux, Inserm, Bordeaux Population Health Research Center, Team Pharmacoepidemiology, UMR 1219, Bordeaux, France.

Soon after the introduction of second-generation antipsychotics, antipsychotic off-label use (OLU) progressively became a common prescribing practice. This evolving practice should be regularly monitored considering the growing number of persons exposed to the adverse effects of antipsychotics. The aim of the present review was to synthesise the literature published over the last 15 years on antipsychotic OLU for mental health symptoms.

View Article and Find Full Text PDF

Background: Paliperidone is a second-generation antipsychotic and the main active metabolite of risperidone, formulated to provide consistent therapeutic effects through an extended-release system, designed to provide consistent therapeutic effects through an extended-release formulation. While commonly used in clinical practice, switching from risperidone to paliperidone, particularly during valproate therapy, can pose challenges due to potential pharmacokinetic interactions that may increase the risk of extrapyramidal symptoms (EPS). Despite clinical observations suggesting these interactions, case reports documenting such adverse effects are scarce.

View Article and Find Full Text PDF

Introduction: Antipsychotic prescriptions are frequent in nursing homes due to the challenging management of symptoms associated with Alzheimer's disease and related neurodegenerative disorders. This study aimed to assess the association between Health-related Quality Of Life (HrQOL) and antipsychotic use in nursing homes.

Methods: This is a cross-sectional study of the KASEHPAD (Karukera Study of Ageing in Nursing Homes) study conducted in six nursing homes in Guadeloupe and Martinique (French West Indies).

View Article and Find Full Text PDF

Background: Changan Granule (CAG) is a drug product developed from a traditional Chinese medicine (TCM) empirical prescription for diarrhea-predominant irritable bowel syndrome (IBS-D). The action mechanism and effective compounds of CAG in the treatment of IBS-D are not well understood.

Purpose: This study aimed to investigate the effectiveness, action mechanism and effective compounds of CAG for treating IBS-D.

View Article and Find Full Text PDF

Background: Many variables may affect approaches of psychiatrists to methamphetamine-associated psychotic disorder (MAP) treatment. This study was aimed to reach adult psychiatrists actively practicing in Turkey through an internet-based survey and to determine their practices and attitudes to MAP treatment.

Methods: In this internet-based study, participants were divided into three groups based on their answers: Those who do not follow-up any MAP patient were group 1 (n = 78), partially involved in the treatment process of at least one patient diagnosed with MAP were group 2 (n = 128), completely involved in the treatment process of at least one patient diagnosed with MAP were group 3 (n = 202).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!